The goal of this prospective single-arm trial is to investigate the accuracy and feasibility of the para-aortic lymph node metastasis prediction model in locally advanced cervical cancer, as well as its impact on patients' prognosis. The main questions it aims to answer are:

• Is the para-aortic lymph node metastasis prediction model accurate and feasible?
• Whether the para-aortic lymph node metastasis prediction model can affect the prognosis of patients.

Inclusion Criteria:

• In 2018, the International Federation of Obstetrics and Gynecology (FIGO) stage was Ib3 IIA2-IVA;
• It was treated initially without surgical and chemotherapy.
• Squamous cell carcinoma, adenocarcinoma and adeno-squamous cell carcinoma were confirmed by histopathology.
• Pelvic MRI ± abdominal CT or MRI or PET/CT were performed before treatment.
• ECOG score:0 ~ 1.
• The expected survival time>6 months;
• There is no absolute contraindication of surgery and and chemoradiotherapy and the patients with good compliance.

Exclusion Criteria:

• History of immune disease who need to take immunosuppressive drugs.
• History of serious mental illness and brain functional disorder.
• Other malignancies were diagnosed within five years or needed treatments.
• Those who are unable or unwilling to accept surgical treatment/sign informed consent/comply with research requirements.
• Without surgical conditions: 1) Chronic renal insufficiency or renal failure; 2) Liver insufficiency; 3)Chronic lung disease with restrictive respiratory dysfunction; 4) Cardiac dysfunction (patients with relative and absolute contraindications to surgery after consultation by cardiac physicians.
• Patients who cannot understand the research regimen and refuse to sign the informed consent form.
• Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.